title: Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
abstract: Coupling therapeutic proteins to targeted nanocarriers can enhance their biodistribution. This is the case for enzyme replacement therapies where intravenously injected enzymes must avoid prolonged blood exposure while reaching body organs. We have shown enhanced tissue targeting of various lysosomal enzymes by coupling to nanocarriers targeted to intercellular adhesion molecule-1 (ICAM-1). Here, we varied design parameters to modify tissue enzyme levels without affecting specific targeting and relative biodistribution. We coupled a-galactosidase (aGal; affected in Fabry disease) to model polymer nanocarriers and varied enzyme load (50 vs. 500 molecules/particle), anti-ICAM surface density (80 vs. 180 molecules/particle), and nanocarrier concentration (1.6 x 1013 vs. 2.4 x 1013 carriers/kg) to render three formulations (45, 449, 555 microg alphaGal/kg). Naked alpha Gal preferentially distributed in blood vs. organs, while nanocarriers shifted biodistribution from blood to tissues. Accumulation in brain, kidneys, heart, liver, lungs, and spleen did not vary among nanocarrier formulations, with enhanced specific tissue accumulation compared to naked aGal. The highest specificity was associated with lowest antibody density and nanocarrier concentration, but highest enzyme load; possibly because of synergistic enzyme affinity toward cell-surface markers. Variation of these parameters significantly increased absolute enzyme accumulation. This strategy may help optimize delivery of lysosomal enzyme replacement and, likely, other protein delivery approaches.
authors.forename: Janet
authors.initials: J
authors.lastname: Hsu
authors.forename: Tridib
authors.initials: T
authors.lastname: Bhowmick
authors.forename: Scott R
authors.initials: SR
authors.lastname: Burks
authors.forename: Joseph P Y
authors.initials: JP
authors.lastname: Kao
authors.forename: Silvia
authors.initials: S
authors.lastname: Muro
mesh_terms: D000818:Animals; D000918:Antibody Specificity / Q000276:immunology; D020099:Coated Materials, Biocompatible / Q000494:pharmacology*; D004337:Drug Carriers / Q000737:chemistry*; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000737:chemistry*; D013499:Surface Properties; D014018:Tissue Distribution / Q000187:drug effects; D000519:alpha-Galactosidase / Q000627:therapeutic use*
chemical_list: D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D018799:Intercellular Adhesion Molecule-1; D000519:alpha-Galactosidase; D016650:Fluorescein-5-isothiocyanate
references.citation: J Inherit Metab Dis. 2013 May;36(3):467-77
references.pmid: 22968581
references.citation: J Gene Med. 2010 Nov;12(11):881-91
references.pmid: 20967919
references.citation: Nat Rev Mol Cell Biol. 2004 Jul;5(7):554-65
references.pmid: 15232573
references.citation: Birth Defects Orig Artic Ser. 1980;16(1):77-84
references.pmid: 7448363
references.citation: Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1156-63
references.pmid: 18565198
references.citation: J Control Release. 2012 Oct 10;163(1):25-33
references.pmid: 22698938
references.citation: Nanomedicine. 2012 Jul;8(5):731-9
references.pmid: 21906578
references.citation: Expert Opin Biol Ther. 2004 Jul;4(7):1167-76
references.pmid: 15268683
references.citation: Mol Genet Metab. 1999 Oct;68(2):268-75
references.pmid: 10527678
references.citation: Cell. 1987 Dec 4;51(5):813-9
references.pmid: 3315233
references.citation: Drug Deliv Transl Res. 2012 Jun 1;2(3):169-86
references.pmid: 24688886
references.citation: Mol Ther. 2006 Jan;13(1):135-41
references.pmid: 16153895
references.citation: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Mar-Apr;2(2):189-204
references.pmid: 20112244
references.citation: J Nucl Med. 2008 Jan;49(1):103-11
references.pmid: 18077519
references.citation: Biomaterials. 2013 Apr;34(13):3459-66
references.pmid: 23398883
references.citation: Curr Med Chem. 2007;14(28):2945-53
references.pmid: 18220730
references.citation: Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
references.pmid: 17092599
references.citation: J Pharmacol Exp Ther. 2006 Jun;317(3):1161-9
references.pmid: 16505161
references.citation: Mol Genet Metab. 2012 Mar;105(3):443-9
references.pmid: 22227322
references.citation: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references.pmid: 2946403
references.citation: J Control Release. 2006 Sep 12;114(3):277-87
references.pmid: 16904220
references.citation: J Control Release. 2011 Feb 10;149(3):323-31
references.pmid: 21047542
references.citation: J Control Release. 2011 Feb 28;150(1):37-44
references.pmid: 21047540
references.citation: J Biol Chem. 2004 Jan 9;279(2):1526-32
references.pmid: 14557264
references.citation: Kidney Int. 1990 Sep;38(3):417-25
references.pmid: 1977950
references.citation: Mol Ther. 2008 Aug;16(8):1450-8
references.pmid: 18560419
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):400-8
references.pmid: 18287213